SYGNIS PHARMA
SYGNIS Pharma AG, a specialty pharmaceutical company, engages in the research, development, and marketing of drugs for the treatment of disorders of the central nervous system (CNS). These include stroke or various forms of dementia. AX200 AX200 is a biological molecule, developed by the company for the treatment of neurodegenerative diseases. It is being tested in a 350 patient, multinational phase II efficacy trial. AX200 is an endogenous protein. As part of the body's own protective action th... e production of AX200 is boosted after brain damage. AX200 displays a multimodal activity: it stops neuronal cell death in the acute phase of the disease while at the same time stimulating the regeneration of the damaged CNS through the stimulation of neurogenesis, as well as arteriogenesis and the reorganisation of neuronal networks. Significant Events The company acquired Amnestix Inc. in 2008. Its business operations focus on the development of novel therapeutics and diagnosis techniques to enhance cognitive and memory functions. History SYGNIS Pharma AG was founded in 1997.
SYGNIS PHARMA
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1997-01-01
Address:
Heidelberg, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.sygnis.de
Total Employee:
1+
Status:
Active
Contact:
+49062213540120
Email Addresses:
[email protected]
Technology used in webpage:
Domain Not Resolving
Similar Organizations
Cardiokine
Cardiokine, Inc., a specialty pharmaceutical company, engages in the development of pharmaceuticals for the prevention and treatment of
Gentium
Gentium S.p.A. is public (GENT - NASDAQ) biopharmaceutical company specializing in the discovery, research, development and manufacture of
MetP Pharma
MetP Pharma is a privately held company, focusing on the nasal delivery of drugs to the systemic circulation and brain.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical companyย focused on theย prevention and treatment of gastrointestinal disorders.
ViroPharma
ViroPharma, a biopharmaceutical company, engages in the development and commercialization of products that address serious diseases
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2018-05-08 | TGR BioSciences | TGR BioSciences acquired by Sygnis Pharma | N/A |
| 2017-06-26 | Expedeon | Expedeon acquired by Sygnis Pharma | 11.5 M EUR |
| 2017-06-26 | Innova Biosciences | Innova Biosciences acquired by Sygnis Pharma | 11.5 M EUR |
| 2016-12-21 | C.B.S. Scientific Company | C.B.S. Scientific Company acquired by Sygnis Pharma | 900 K USD |
| 2008-06-08 | Amnestix | Amnestix acquired by Sygnis Pharma | 6.3 M USD |
More informations about "Sygnis Pharma"
SYGNIS AG: SYGNIS AG gibt vollständige Integration der kürzlich ...
Apr 11, 2017 Pilar de la Huerta Co-CEO/CBDO Tel.: +34 91 192 36 50 E-Mail: [email protected]. MC Services AG Raimund Gabriel Managing Partner Tel.: +49 89 โฆSee details»
Ygnis - Expert in heating solutions for commercial applications
Die Firma YGNIS AG in Ruswil ist ein sich stetig weiter entwickelnder, international führender Anbieter von Produkten für die Wärmeerzeugung und gehört der französischen Groupe โฆSee details»
Home | ACV Ygnis
Recientemente las soluciones colectivas en agua caliente sanitaria de ACV han entrado a formar parte del catálogo de YGNIS, consolidando así uno de los mayores porfolios en soluciones de โฆSee details»
SYGNIS AG Profile | The Scientist
SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Innova Biosciences, and C.B.S. Scientific Company, today announced it โฆSee details»
SYGNIS passt Organisation an neue Geschäftstätigkeit an
SYGNIS Pharma AG gab die Einstellung seines therapeutischen Entwicklungsprojektes KIBRA und eine Anpassung der Organisation an die neue Geschäftstätigkeit der Gesellschaft โฆSee details»
Legal Information - Ygnis Germany
This website is published by Ygnis AG. A Limited Company. Share capital : 2 900 000 CHF. Registered office : 31-33, Wolhuserstrasse -6017 Ruswil (Switzerland) Registration number: โฆSee details»
Home - Ygnis Italia
Ygnis è stato creato più di 80 anni fa. Scopri di più sulla nostra storia. Ulteriori informazioni. Chiedi per un preventivo. Se vuoi sviluppare il tuo progetto con i nostri prodotti, puoi chiedere un โฆSee details»
SYGNIS | LinkedIn
SYGNIS | 572 Follower:innen auf LinkedIn. SYGNIS is a German stocklisted company devoted to the development of novel, superior tools for molecular biology that play key roles in changing โฆSee details»
WELCOME TO YGNIS AG SWITZERLAND, GERMANY, AUSTRIA
YGNIS AG SWITZERLAND Wolhuserstrasse 1-33 6017, Ruswil, Switzerland Tel. +41 (0) 41 496 91 20 Fax +41 (0) 41 496 91 21 [email protected] www.ygnis.comSee details»
SYGNIS AG - Lab Manager
May 13, 2018 Organization profile for SYGNIS AG on Lab Manager. Is the form not loading? If you use an ad blocker or browser privacy features, try turning them off and refresh the page.See details»
Firmenverzeichnis - SYGNIS Pharma AG - heidelberg.de
E-Mail [email protected]. Telefon 06221 454-6. Fax 06221 454-700. Beschreibung. Die SYGNIS Pharma AG ist ein im Prime Standard der Deutschen Börse gelistetes spezialisiertes Pharma โฆSee details»
Sygnis Pharma AG โ Rhein-Neckar-Wiki
Die Sygnis Pharma AG ist ein Biotechnologieunternehmen mit Sitz in Heidelberg, das sich auf die Enwicklung und Vermarktung neuartiger molekularbiologischer Technologien konzentriert.. โฆSee details»
SYGNIS SA : Aktionäre Vorstände Geschäftsführer und โฆ
SYGNIS SA : Vorstellung des Unternehmens SYGNIS SA, Aktionäre, Vorstände und Berufsbeschreibung, Finanzstärkerating, offizielle Mitteilungen, Kontaktdaten und โฆSee details»
Home - Ygnis Suisse
Die Firma YGNIS AG in Ruswil ist ein sich stetig weiter entwickelnder, international führender Anbieter von Produkten für die Wärmeerzeugung und gehört der französischen Groupe โฆSee details»
Sygnis AG: Science and business rolled into one - European ...
Jul 4, 2017 German-Spanish biotech Sygnis AG has made changes to its management team and supervisory board. Heikki Lanckriet, who was previously Co-CEO, will become sole CEO โฆSee details»
Sygnis Pharma AG - Rhein-Neckar-Wiki
Nov 29, 2006 Die Sygnis Pharma AG ist ein Biotechnologieunternehmen mit Sitz in Heidelberg, das sich auf die Enwicklung und Vermarktung neuartiger molekularbiologischer Technologien โฆSee details»
SYGNIS Bioscience GmbH & Co. KG, Heidelberg - North Data
SYGNIS Bioscience GmbH & Co. KG, Heidelberg, Amtsgericht Frankfurt am Main HRA 42769: Netzwerk, WirtschaftsinfosSee details»
Ygnis - Expert in heating solutions for commercial applications
Born in Switzerland in 1943, Ygnis joined Groupe Atlantic in 2003 and became an international brand. Ygnis is specialised in condensing gas boilers, pressurised boilers, hot water storage, โฆSee details»
Sygnis bekommt zwei neue Vorstandsmitglieder - 3Druck.com
Am 9. Januar 2023 ernannte der Aufsichtsrat von Sygnis Olga Czerwiลska und Joanna Danaj zu Vorstandsmitgliedern. Im Gegenzug trat der derzeitigeSee details»
Brennwert-Kompaktwärmezentralefür Gas 40 - 100 kW
YGNIS AG Heizkessel und Wassererwärmer Wolhuserstrasse 31/33 6017 Ruswil CH Telefon +41 (0) 41 496 91 20 Telefax +41 (0) 41 496 91 21 E-mail: [email protected] www.ygnis.ch โฆSee details»